1. Home
  2. BLFY vs IKT Comparison

BLFY vs IKT Comparison

Compare BLFY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Foundry Bancorp

BLFY

Blue Foundry Bancorp

HOLD

Current Price

$13.07

Market Cap

185.3M

Sector

Finance

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.69

Market Cap

201.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLFY
IKT
Founded
1939
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.3M
201.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BLFY
IKT
Price
$13.07
$1.69
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$10.00
$6.00
AVG Volume (30 Days)
483.7K
522.9K
Earning Date
01-21-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,731,000.00
N/A
Revenue This Year
$19.85
N/A
Revenue Next Year
$20.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.52
N/A
52 Week Low
$7.61
$1.33
52 Week High
$13.55
$3.32

Technical Indicators

Market Signals
Indicator
BLFY
IKT
Relative Strength Index (RSI) 60.49 47.33
Support Level $12.77 $1.63
Resistance Level $13.55 $1.88
Average True Range (ATR) 0.36 0.10
MACD -0.02 -0.02
Stochastic Oscillator 69.65 24.15

Price Performance

Historical Comparison
BLFY
IKT

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: